PL2740489T3 - Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki - Google Patents
Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustkiInfo
- Publication number
- PL2740489T3 PL2740489T3 PL12819899T PL12819899T PL2740489T3 PL 2740489 T3 PL2740489 T3 PL 2740489T3 PL 12819899 T PL12819899 T PL 12819899T PL 12819899 T PL12819899 T PL 12819899T PL 2740489 T3 PL2740489 T3 PL 2740489T3
- Authority
- PL
- Poland
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- pancreatic cancer
- pancreatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011171310 | 2011-08-04 | ||
| EP12819899.1A EP2740489B1 (en) | 2011-08-04 | 2012-08-03 | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2740489T3 true PL2740489T3 (pl) | 2017-06-30 |
Family
ID=47629400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12819899T PL2740489T3 (pl) | 2011-08-04 | 2012-08-03 | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9409993B2 (pl) |
| EP (1) | EP2740489B1 (pl) |
| JP (1) | JP6003650B2 (pl) |
| KR (1) | KR102041832B1 (pl) |
| CN (1) | CN103717238B (pl) |
| AU (1) | AU2012290949B2 (pl) |
| BR (1) | BR112014002619A2 (pl) |
| CA (1) | CA2844037C (pl) |
| DK (1) | DK2740489T3 (pl) |
| ES (1) | ES2609846T3 (pl) |
| HU (1) | HUE030130T2 (pl) |
| MX (1) | MX351414B (pl) |
| PL (1) | PL2740489T3 (pl) |
| PT (1) | PT2740489T (pl) |
| RU (1) | RU2630638C2 (pl) |
| WO (1) | WO2013018886A1 (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5644110B2 (ja) | 2008-08-05 | 2014-12-24 | 東レ株式会社 | 癌の検出方法 |
| RU2498819C2 (ru) | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| JP5906739B2 (ja) | 2010-02-04 | 2016-04-20 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| CN102821789B (zh) | 2010-02-04 | 2016-03-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| CN102822199B (zh) | 2010-02-04 | 2014-10-15 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| HUE030102T2 (en) | 2010-02-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer |
| WO2011096535A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| PT2532365T (pt) | 2010-02-04 | 2016-07-28 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro |
| JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
| WO2013018891A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| JP6015448B2 (ja) | 2011-08-04 | 2016-10-26 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| HUE030130T2 (en) | 2011-08-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer |
| CN103717740B (zh) | 2011-08-04 | 2015-10-21 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| PL2740795T3 (pl) | 2011-08-04 | 2017-04-28 | Toray Industries, Inc. | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi |
| PL2818483T3 (pl) | 2012-02-21 | 2018-01-31 | Toray Industries | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi |
| AU2013223147B2 (en) | 2012-02-21 | 2017-10-05 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| PL2818482T3 (pl) | 2012-02-21 | 2019-11-29 | Toray Industries | Kompozycja farmaceutyczna do leczenia nowotworu |
| KR102005308B1 (ko) | 2012-02-21 | 2019-07-30 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| PL2832366T3 (pl) * | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
| AU2013241036B2 (en) * | 2012-03-30 | 2017-07-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| BR112015001100A2 (pt) | 2012-07-19 | 2018-03-27 | Toray Industries, Inc. | método de detecção de câncer |
| PT2876446T (pt) | 2012-07-19 | 2019-03-25 | Toray Industries | Método para deteção de cancro |
| TR201819812T4 (tr) | 2013-08-09 | 2019-01-21 | Toray Industries | Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim |
| WO2015076425A1 (ja) * | 2013-11-25 | 2015-05-28 | リンク・ジェノミクス株式会社 | 新規モノクローナル抗体 |
| JP2018500932A (ja) * | 2014-12-22 | 2018-01-18 | アナーパ バイオテック エー／エス | 標的核酸のマルチプレックス検出のためのデュアルクエンチングアッセイ |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| JP7206590B2 (ja) | 2016-10-28 | 2023-01-18 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| US20210121562A1 (en) | 2018-03-30 | 2021-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| JPWO2021182570A1 (pl) | 2020-03-12 | 2021-09-16 | ||
| WO2021182574A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| KR20220153615A (ko) | 2020-03-12 | 2022-11-18 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
| WO2021182573A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2021182571A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| EP4360649A1 (en) | 2021-06-23 | 2024-05-01 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| MX2023014498A (es) | 2021-06-23 | 2024-01-25 | Toray Industries | Medicamento para el tratamiento y/o prevencion de cancer. |
| EP4378478A1 (en) | 2021-07-27 | 2024-06-05 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| JPWO2023008461A1 (pl) | 2021-07-27 | 2023-02-02 | ||
| EP4378476A1 (en) | 2021-07-27 | 2024-06-05 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| KR20240051956A (ko) | 2021-09-03 | 2024-04-22 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| JPWO2024005123A1 (pl) | 2022-06-30 | 2024-01-04 | ||
| AU2023329563A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| AU2023329564A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| AU2023329558A1 (en) | 2022-08-24 | 2025-02-27 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| WO2024048541A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| WO2024048542A1 (ja) | 2022-08-30 | 2024-03-07 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
| US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| EP1870466A3 (en) | 1998-07-14 | 2008-03-19 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
| US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| EP1187915A2 (en) | 1999-04-02 | 2002-03-20 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP1224285A4 (en) | 1999-10-29 | 2004-12-08 | Human Genome Sciences Inc | 27 HUMAN SECRETED PROTEINS |
| US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| PL366626A1 (pl) | 2000-03-29 | 2005-02-07 | Corixa Corporation | Kompozycje oraz sposoby leczenia i diagnozowania raka płuc |
| US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
| RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
| AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
| WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| EP1516049A4 (en) | 2001-05-11 | 2006-01-11 | Corixa Corp | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG CANCER |
| US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| EP1575480A4 (en) | 2002-02-22 | 2008-08-06 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
| US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
| US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP2179742A1 (en) | 2002-11-26 | 2010-04-28 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
| WO2004097051A2 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing aml and mds differential gene expression |
| EP1639090A4 (en) | 2003-06-09 | 2008-04-16 | Univ Michigan | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
| US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
| US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
| EP2361929A1 (en) | 2004-01-26 | 2011-08-31 | Debiovision Inc. | Neoplasm-specific polypeptides and their use |
| PT1735348E (pt) | 2004-03-19 | 2012-07-24 | Imclone Llc | Anticorpo anti-receptor do factor de crescimento humano |
| WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
| WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
| JP2008528486A (ja) | 2005-01-21 | 2008-07-31 | ジェネンテック・インコーポレーテッド | Ｈｅｒ抗体の一定投薬 |
| WO2006089212A2 (en) | 2005-02-18 | 2006-08-24 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
| CA2602088C (en) | 2005-03-11 | 2021-07-27 | Ciphergen Biosystems, Inc. | Biomarkers for ovarian cancer and endometrial cancer |
| JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| CN101384273B (zh) * | 2006-01-05 | 2013-07-10 | 俄亥俄州立大学研究基金会 | 胰腺内分泌和腺泡肿瘤中的微小rna表达异常 |
| WO2007095186A2 (en) | 2006-02-14 | 2007-08-23 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| WO2008073162A2 (en) | 2006-08-17 | 2008-06-19 | Cell Signaling Technology, Inc. | Lysine acetylation sites |
| US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| WO2008031041A2 (en) | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
| DK3106873T3 (da) | 2007-10-25 | 2019-09-23 | Toray Industries | Fremgangsmåde til detektering af cancer |
| JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
| CR20180483A (es) | 2008-03-18 | 2018-12-05 | Genentech Inc | COMBINACIONES DE UN CONJUNGADO ANTICUERPO-FÁRMACO ANTI-HER2 Y AGENTES QUIMIOTERAPÉUTICOS (Divisional 11678) |
| RU2498819C2 (ru) * | 2008-08-05 | 2013-11-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей |
| US8454968B2 (en) | 2008-08-05 | 2013-06-04 | Toray Industries, Inc. | Method for inducing immunity with a peptide fragment from human CAPRIN-1 |
| JP5644110B2 (ja) | 2008-08-05 | 2014-12-24 | 東レ株式会社 | 癌の検出方法 |
| CA2771441C (en) | 2009-08-19 | 2016-10-11 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in ffpe material |
| KR101545914B1 (ko) | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
| RU2418587C1 (ru) * | 2010-01-21 | 2011-05-20 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") | Способ лечения злокачественных опухолей головного мозга |
| CN102821789B (zh) | 2010-02-04 | 2016-03-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| WO2011096535A1 (ja) | 2010-02-04 | 2011-08-11 | 東レ株式会社 | 癌の治療及び／又は予防のための医薬品 |
| CN102822199B (zh) | 2010-02-04 | 2014-10-15 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| PT2532365T (pt) | 2010-02-04 | 2016-07-28 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro |
| HUE030102T2 (en) | 2010-02-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment and / or prevention of cancer |
| JP5906739B2 (ja) | 2010-02-04 | 2016-04-20 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| WO2012005550A2 (ko) | 2010-07-08 | 2012-01-12 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
| CN103261224B (zh) | 2010-07-26 | 2015-10-07 | 瑟维尔实验室 | 用于肝癌治疗的方法和组合物 |
| ES2618026T3 (es) * | 2011-08-04 | 2017-06-20 | Toray Industries, Inc. | Composición farmacológica para el tratamiento y/o la prevención del cáncer |
| HUE030130T2 (en) | 2011-08-04 | 2017-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of pancreatic cancer |
| WO2013018891A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| JP6015448B2 (ja) * | 2011-08-04 | 2016-10-26 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| JP6094220B2 (ja) | 2011-08-04 | 2017-03-15 | 東レ株式会社 | 膵臓癌の検出方法 |
| CN103717740B (zh) | 2011-08-04 | 2015-10-21 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| PL2740795T3 (pl) * | 2011-08-04 | 2017-04-28 | Toray Industries, Inc. | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi |
| KR102005308B1 (ko) * | 2012-02-21 | 2019-07-30 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| PL2818483T3 (pl) * | 2012-02-21 | 2018-01-31 | Toray Industries | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi |
| PL2818482T3 (pl) * | 2012-02-21 | 2019-11-29 | Toray Industries | Kompozycja farmaceutyczna do leczenia nowotworu |
| AU2013223147B2 (en) * | 2012-02-21 | 2017-10-05 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| AU2013241036B2 (en) | 2012-03-30 | 2017-07-20 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
| PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
-
2012
- 2012-08-03 HU HUE12819899A patent/HUE030130T2/en unknown
- 2012-08-03 CN CN201280038490.3A patent/CN103717238B/zh active Active
- 2012-08-03 WO PCT/JP2012/069829 patent/WO2013018886A1/ja active Application Filing
- 2012-08-03 EP EP12819899.1A patent/EP2740489B1/en active Active
- 2012-08-03 US US14/236,818 patent/US9409993B2/en active Active
- 2012-08-03 BR BR112014002619-0A patent/BR112014002619A2/pt not_active Application Discontinuation
- 2012-08-03 RU RU2014108047A patent/RU2630638C2/ru active
- 2012-08-03 PT PT128198991T patent/PT2740489T/pt unknown
- 2012-08-03 AU AU2012290949A patent/AU2012290949B2/en active Active
- 2012-08-03 KR KR1020147005897A patent/KR102041832B1/ko active Active
- 2012-08-03 PL PL12819899T patent/PL2740489T3/pl unknown
- 2012-08-03 DK DK12819899.1T patent/DK2740489T3/en active
- 2012-08-03 JP JP2012543820A patent/JP6003650B2/ja active Active
- 2012-08-03 ES ES12819899.1T patent/ES2609846T3/es active Active
- 2012-08-03 CA CA2844037A patent/CA2844037C/en active Active
- 2012-08-03 MX MX2014001372A patent/MX351414B/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN103717238A (zh) | 2014-04-09 |
| AU2012290949B2 (en) | 2017-03-02 |
| US9409993B2 (en) | 2016-08-09 |
| EP2740489A1 (en) | 2014-06-11 |
| AU2012290949A1 (en) | 2014-03-20 |
| CA2844037C (en) | 2020-07-14 |
| US20140308283A1 (en) | 2014-10-16 |
| HUE030130T2 (en) | 2017-04-28 |
| EP2740489A4 (en) | 2015-03-04 |
| MX351414B (es) | 2017-10-13 |
| JPWO2013018886A1 (ja) | 2015-03-05 |
| ES2609846T3 (es) | 2017-04-24 |
| EP2740489B1 (en) | 2016-10-05 |
| MX2014001372A (es) | 2014-03-21 |
| KR102041832B1 (ko) | 2019-11-08 |
| KR20140064835A (ko) | 2014-05-28 |
| PT2740489T (pt) | 2017-01-10 |
| CN103717238B (zh) | 2016-10-12 |
| WO2013018886A1 (ja) | 2013-02-07 |
| RU2630638C2 (ru) | 2017-09-11 |
| JP6003650B2 (ja) | 2016-10-05 |
| RU2014108047A (ru) | 2015-09-10 |
| BR112014002619A2 (pt) | 2018-10-09 |
| CA2844037A1 (en) | 2013-02-07 |
| DK2740489T3 (en) | 2017-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2740489T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático | |
| HUE046788T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
| PL2532365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| PL2532743T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka | |
| PT2832365T (pt) | Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático | |
| PL2740793T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi | |
| PL2740796T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| PL2740794T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub profilaktyki nowotworów | |
| HUE036425T2 (hu) | Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére | |
| PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
| PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
| PT2532367T (pt) | Agente farmacêutico para o tratamento e/ou prevenção do cancro | |
| PL2532366T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
| HUE042081T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
| PL2818482T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| PL2824114T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
| IL225471A0 (en) | Preparations and methods for the prevention and treatment of cancer | |
| PL2532680T3 (pl) | Kompozycja medyczna do leczenia raka i/lub zapobiegania | |
| PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
| IL223189A0 (en) | Methods of treatment of pancreatic cancer | |
| GB201302652D0 (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases | |
| HK1201730A1 (en) | Treatment agent and or prophylactic agent for side effects of cancer drugs | |
| SG11201400976WA (en) | Methods and pharmaceutical compositions for treating cancer | |
| IL221238A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of cancer |